CALCIMIMETIC ADHERENCE AND PREFERENCE IN THE MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN EUROPE: A PILOT STUDY

被引：0

作者：

Louie, Karly ^{[1
]}

Nduka, Chidozie ^{[1
]}

Taylor, Jo ^{[2
]}

Hall, Matthew ^{[3
]}

Aucella, Filippo ^{[4
]}

Artero, Josep ^{[5
]}

Na, Pablo Ure ^{[6
]}

Labriola, Laura ^{[7
]}

Andersson, Per-Olof ^{[8
]}

Evenepoel, Pieter ^{[9
]}

Oliva, Juan Carlos Gonzalez ^{[10
]}

Pisoni, Ronald ^{[11
]}

Fouqueray, Bruno ^{[12
]}

Horne, Robert ^{[13
]}

机构：

[1] AMGEN Ltd, Ctr Observat Res, Uxbridge, Middx, England

[2] Dorset Cty Hosp, Dorchester, England

[3] Nottingham Univ Hosp, Nottingham, England

[4] Fdn IRCCS Casa Sollievo Sofferenza, Nephrol & Dialysis Unit, San Giovanni Rotondo, Italy

[5] Hosp Univ Girona, Serv Nefrol, Girona, Spain

[6] Necker Enfant Malad Hosp, Serv Nephrol Dialyse, Paris, France

[7] Catholic Univ Louvain, Clin Univ St Luc, Dept Nephrol, Brussels, Belgium

[8] Vrinnevisjukhuset, Med Kliniken, Norrkoping, Sweden

[9] Univ Hosp Leuven, Div Nephrol, Leuven, Belgium

[10] Fdn Privada Hosp Mollet, Barcelona, Spain

[11] Arbor Res Collaborat Hlth, Ann Arbor, MI USA

[12] Amgen GmbH, Rotkreuz, Switzerland

[13] UCL, Sch Pharm, London, England

来源：

NEPHROLOGY DIALYSIS TRANSPLANTATION | 2021年 / 36卷

关键词：

D O I：

暂无

中图分类号：

R3 [基础医学]; R4 [临床医学];

学科分类号：

1001 ; 1002 ; 100602 ;

摘要：

MO524

引用

页数：2

共 50 条

[21] Exploring the potential value of improved care for secondary hyperparathyroidism with a novel calcimimetic therapy
Stollenwerk, Bjoern
Iannazzo, Sergio
Cooper, Kerry
Belozeroff, Vasily
JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (10) : 1110 - 1115
[22] A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism
Goodman, WG
Frazao, JM
Goodkin, DA
Turner, SA
Liu, W
Coburn, JW
KIDNEY INTERNATIONAL, 2000, 58 (01) : 436 - 445
[23] Nonclinical Safety Profile of Etelcalcetide, a Novel Peptide Calcimimetic for the Treatment of Secondary Hyperparathyroidism
Fielden, Mark R.
Dean, Charles, Jr.
Black, Kurt
Sawant, Satin G.
Subramanian, Raju
Tomlinson, James E.
Walter, Sarah
Zimmermann, Cameron
Griggs, Mark W.
McKeon, Marie E.
Lewis, Elise M.
Beevers, Carol
Pyrah, Ian
INTERNATIONAL JOURNAL OF TOXICOLOGY, 2016, 35 (03) : 294 - 308
[24] Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials
Goodman, WG
PEDIATRIC NEPHROLOGY, 2003, 18 (12) : 1206 - 1210
[25] Management of secondary hyperparathyroidism
Cunningham, J
THERAPEUTIC APHERESIS AND DIALYSIS, 2005, 9 : S35 - S40
[26] The management of secondary hyperparathyroidism
Cunningham, J.
ANNALES D ENDOCRINOLOGIE, 2006, 67 (02) : 176 - 179
[27] Surgical outcomes of parathyroidectomy for secondary hyperparathyroidism resistant to calcimimetic treatment: A retrospective single-center cohort study
Okada, Manabu
Tominaga, Yoshihiro
Ichimori, Toshihiro
Tomosugi, Toshihide
Hiramitsu, Takahisa
Tsuzuki, Toyonori
THERAPEUTIC APHERESIS AND DIALYSIS, 2021, 25 (02) : 188 - 196
[28] Clinical Benefits of an Adherence Monitoring Program in the Management of Secondary Hyperparathyroidism with Cinacalcet: Results of a Prospective Randomized Controlled Study
Ogna, Valentina Forni
Pruijm, Menno
Zweiacker, Carole
Wuerzner, Gregoire
Tousset, Eric
Burnier, Michel
BIOMED RESEARCH INTERNATIONAL, 2013, 2013
[29] Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats
Chin, J
Miller, SC
Wada, M
Nagano, N
Nemeth, EF
Fox, J
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2000, 11 (05): : 903 - 911
[30] Amgen receives FDA approval for calcimimetic used to treat secondary hyperparathyroidism in dialysis patients
不详
DIALYSIS & TRANSPLANTATION, 2004, 33 (05) : 234 - 234

← 1 2 3 4 5 →